Nicki Thompson
Chief Executive Officer Trimtech Therapeutics
Nicki Thompson is Chief Executive Officer of TRIMTECH Therapeutics, bringing more than 25 years of leadership experience across pharma and biotech. She previously served as founding CEO of Amphista Therapeutics, where she raised approximately $150M and secured major pharmaceutical partnerships valued at over $2B. Her earlier career includes senior positions at Roche and GSK, with a focus on external drug discovery and business development.
Seminars
Thursday 10th September 2026
How Seed Stage Biotech Navigate BD Engagement
2:00 pm
- Discussing unique constraints of seed-stage companies when approaching BD engagement
- Maintaining relationships with big pharma and VCs when data is early and limited
- Outlining opportunities for creative deal structures, and when and where they would be appropriate
Thursday 10th September 2026
Expansion Potential: Advancing Degradation into New Indications & Beyond “Classic” Degraders
8:45 am
- Highlighting innovations in non-E3 ligase mechanisms, and discussing which modality fits which disease class?
- Overcoming target identification bottlenecks for immunology and CNS targets. Should companies prioritize diseases with validated pathways but poor druggability, or tissues where degrader PK/ PD is already known?
- As pharma lean towards platforms with broad disease reach, what non-oncology data “moves the needle”?
